Using OCT Angiography to Diagnose and Evaluate Wet AMD
Optical Coherence Tomography Angiography in Neovascular Age-related Macular Degeneration
This study is testing if a special imaging technique can help doctors find new blood vessels in older adults with wet age-related macular degeneration and see how blood flow might affect the condition.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 160 (estimated) |
| Ages | 50 Years to 100 Years |
| Sex | All |
| Sponsor | Oregon Health and Science University Academic / other |
| Locations | 1 site (Portland, Oregon) |
| Trial ID | NCT02253030 on ClinicalTrials.gov |
What this trial studies
This observational study aims to utilize optical coherence tomography (OCT) angiography to diagnose the presence of new blood vessels in patients with wet age-related macular degeneration (AMD). It will also evaluate patients undergoing treatment for this condition and investigate whether reduced blood flow to the choroid is a risk factor for developing wet AMD. The study will include adults aged 50 and older with treatment-naïve neovascular AMD and healthy individuals for comparison. The methodology focuses on advanced imaging techniques to enhance understanding and management of wet AMD.
Who should consider this trial
Good fit: Ideal candidates include adults aged 50 and older with treatment-naïve neovascular AMD showing active new blood vessel growth.
Not a fit: Patients with significant kidney disease, severe hypertension, or those who have previously undergone macular laser treatment may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved diagnostic and treatment strategies for patients with wet AMD.
How similar studies have performed: Other studies utilizing OCT angiography have shown promise in diagnosing and managing retinal conditions, indicating a potential for success in this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria (Groups with wet AMD): * Adults aged 50 and older with clinical findings of treatment-naïve (never treated) neovascular AMD with active new blood vessel growth confirmed by clinical testing will be considered Inclusion Criteria (Group with healthy eyes) * No evidence of retinal disease * Refractive error greater than +3.00 diopters or -7.00 diopters (glasses Rx) * No recent eye surgery in the last 4 months * No significant cataract to interfere with the quality of the imaging Exclusion Criteria (All Groups): * Inability to give informed consent * Significant kidney disease * Blood pressure greater than 180/110 * Previous macular laser treatment * Inability to maintain stable fixation during OCT imaging * Visual acuity worse than 20/200
Where this trial is running
Portland, Oregon
- Casey Eye Institute, Oregon Health & Science University — Portland, Oregon, United States (Recruiting)
Study contacts
- Principal investigator: Steven Bailey, MD — Oregon Health and Science University
- Study coordinator: George Pacheco, COA
- Email: pachecge@ohsu.edu
- Phone: 503-494-7398
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.